|
|
|
|
Preventing—with the goal of eradicating—sudden cardiac death in children
Sudden cardiac death in a child is an uncommon but devastating occurrence. Using the primary and secondary prevention strategies discussed here, it can also be an avoidable one.
|
| |
More>>
|
|
|
|
|
|
Study diminshes value of beta blockers in treatment of hypertension
Beta blockers, touted for 3 decades as first-line drugs in the treatment of hypertension, are less than optimum in comparison to other antihypertensive drugs and raise the risk of stroke, according to a meta-analysis published online by The Lancet.
|
| |
More>>
|
|
|
|
|
|
How to get your high-risk patients to the new NCEP goals
Now that the optimal LDL-cholesterol level for patients with coronary heart disease or its risk equivalents is substantially below 100 mg/dL, consider aggressive lipid-lowering strategies in this group. With the advent of more powerful statins, combination therapy, and newer nonstatin agents, you can help a significantly greater proportion of your patients attain their lipid goals.
|
| |
More>>
|
|
|
|
|
|
Who needs lipid-lowering drugs?
Except for quitting smoking, lowering of LDL cholesterol may offer a greater reduction in cardiovascular risk to vulnerable patients than any other strategy now available. Here is a handy reference for your full range of options.
|
| |
More>>
|
|
|
